Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $46.00 → $33.00 | Outperform | Leerink Partners |
| 12/8/2023 | $41.00 | Overweight | Wells Fargo |
| 5/18/2023 | $48.00 | Buy | Canaccord Genuity |
| 4/13/2023 | $44.00 | Outperform | Robert W. Baird |
| 12/14/2022 | $33.00 | Buy | Stifel |
| 12/7/2022 | $42.00 | Overweight | JP Morgan |
| 9/1/2022 | $36.00 | Buy | Citigroup |
| 7/20/2022 | $33.00 | Outperform | SVB Leerink |
10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events. Evercore 7th Annual HealthCONx Conference Members of Pliant's senior management will meet with investors on Tuesday, December 3, 2024.Citi 2024 Global Healthcare Conference Members of Pliant's senior management will meet with investors on Wednesday, December 4, 2024.Piper Sandler 36th Annual Healthcare Conference Bernard Coulie, M.D., Ph.D. Pliant's President and Chief Exe
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease
Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placeboStatistically significant improvement in alkaline phosphatase (ALP) levels over 24 weeks compared to placeboContinued improvement in hepatocyte function and bile flow by contrast MRI imaging observed from Week 12 to Week 24FDA guidance provided clarity on next steps of PSC development programSOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced positive 24-week data from the 320 mg cohort of
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial. The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant's website. The live audio of the conference call c
Leerink Partners resumed coverage of Pliant Therapeutics with a rating of Outperform and set a new price target of $33.00 from $46.00 previously
Wells Fargo initiated coverage of Pliant Therapeutics with a rating of Overweight and set a new price target of $41.00
Canaccord Genuity initiated coverage of Pliant Therapeutics with a rating of Buy and set a new price target of $48.00
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)